Deafness associated with the use of Bortezomib in multiple myeloma.
Chim
C S
CS
Wong
L G
LG
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001897:Boronic Acids / Q000009:adverse effects*; D000069286:Bortezomib; D017809:Fatal Outcome; D005260:Female; D006319:Hearing Loss, Sensorineural / Q000139:chemically induced*; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood / Q000187:drug effects; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000503:physiopathology; D011719:Pyrazines / Q000009:adverse effects*; D012307:Risk Factors
D000970:Antineoplastic Agents; D001897:Boronic Acids; D007070:Immunoglobulin A; D011719:Pyrazines; D000069286:Bortezomib